Friday, May 20, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Echinacea as a potential force against coronavirus infections

by Medical Finance
in Coronavirus
Study: Echinacea as a Potential Force against Coronavirus Infections? A Mini-Review of Randomized Controlled Trials in Adults and Children. Image Credit: Nataliia Kuznetcova/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

The spread of infections from animals to humans is referred to as zoonosis. Earlier zoonotic episodes include the transmission of Yersinia pestis (plague) from a rodent flea or Ebola spreading from apes to humans, resulting in millions of deaths in Europe and Africa.

Respiratory viruses such as influenza have been detected crossing species boundaries from animals to people on several occasions, resulting in catastrophic illness outbreaks such as the Spanish (H1N1), Asian (H2N2), or Hong Kong (H3N2) flu epidemics, as well as the more recent avian H5N1 flu epidemic.

Study: Echinacea as a Potential Force against Coronavirus Infections? A Mini-Review of Randomized Controlled Trials in Adults and Children. Image Credit: Nataliia Kuznetcova/ShutterstockStudy: Echinacea as a Potential Force against Coronavirus Infections? A Mini-Review of Randomized Controlled Trials in Adults and Children. Image Credit: Nataliia Kuznetcova/Shutterstock


Rather than pure immunological activation, echinacea extracts alter the immune system in a way that is best defined as adaptive immune regulation. Echinacea lowered the expression of the inflammatory cytokines tumor necrosis factor TNF-α and interleukin IL-1-β by up to 24% and elevated the anti-inflammatory cytokine IL-10 when compared to baseline.

In addition, the synthesis of the immune-response modifying and antiviral interferon IFN-ϒ increased by up to 50%.

Echinacea’s immunomodulatory processes also include significant activation of the endocannabinoid system (ECS) via the cannabinoid receptor type 2 (CB2) by particular N-alkylamides.

Several of these bioactive N-alkylamides have structural similarities to endocannabinoids, which have an anti-inflammatory effect on the cytokine milieu at low nanomolar concentrations. Activation of the ECS during COVID-19 progression could be a new way to combat systemic inflammation and the cytokine storm. The goal of this review, which was carried out by a group of researchers from a variety of multi-national institutions, was to find clinical studies evaluating coronavirus infections in the context of Echinacea administration and to assess preventive and therapy advantages.

The study

The initial clinical study was conducted as a double-blinded, placebo-controlled, monocentric randomized control trial (RCT) at Cardiff University in the United Kingdom. Participants aged 18 and above from Cardiff, Wales, were asked to apply a 3 x 0.9 mL solution daily for four months. A commercial preparation, standardized to contain 5 mg/100 g of dodecatetraenoic acid isobutylamide based on high-performance liquid chromatography measurements, was used to extract the hydro-ethanolic extract from freshly harvested aerial parts of Echinacea purpurea to 95% supplemented with 5% Echinacea purpurea roots extract.

In comparison to 115 samples from the control group, the Echinacea group provided 86 nasopharyngeal samples, of which 54 and 74 samples, respectively, were positive for any respiratory virus. The presence of enveloped viruses was confirmed in 24 and 47 samples, respectively, and the resulting odds ratio OR = 0.49 was considered to be statistically significant.  Nine CoV-229E, 11 CoV-HKU1, and one CoV-OC43 infection were found in the Echinacea group, totaling 21 coronavirus infections. In the placebo group, 15 CoV-229E, 17 CoV-HKU1, and one CoV-OC43 infection were found, totaling 33 infections.

The odds of getting coronavirus infection were identical to the overall results for cumulated enveloped viruses, with OR = 0.63. In a group of patients who had actively used their patient diary to report adverse events and/or cold-related symptoms, the prevention effects on coronaviruses were statistically significant. Echinacea had a 5.5% overall incidence rate compared to 14.6% for placebo.

The same Echinacea extract packaged in tablets was given to children aged 4 to 12 years old residing in central Switzerland in a second blinded, multi-center RCT. As a control, the scientists used a low-dose vitamin C 3 x of 50 mg/d. The commercial product was a child Echinacea formulation with a daily dosing recommendation of 1200 mg for children over the age of four. In the winter of 2016/17, 203 mostly healthy youngsters were participated in this study, with N = 103 receiving Echinacea 3 400 mg/d and N = 98 receiving Vitamin C 3 x 50 mg/d.

Two CoV episodes pre-existed in each group at the time of inclusion, therefore they were used to assess treatment benefits rather than prevention. Cycle threshold (Ct) values for separate incidence tests were calculated in this investigation, evaluating the number of RNA copies as a measure of virus concentration in the nasopharyngeal sample.

The lower the viral load reflected by the sample’s RNA level, the higher the Ct-value. Echinacea boosted the average Ct-value by 6.1 Ct units from 25.0 to 31.1, showing a considerable reduction in coronavirus concentration of -1.81 log or 98.5% when compared to the control. For variants NL63 and OC43, Ct values of 5.53 and 11.92 were reported, resulting in a virus log reduction of 1.67 and 3.59, respectively, corresponding to an absolute virus reduction of 97.8% and 99.97%.

Implications

Echinacea purpurea (L.) Moench extracts have been shown to have direct antiviral efficacy against a variety of respiratory infections, including coronaviruses. This extract promotes the tonic synthesis of IFN-ϒ and inhibits the production of inflammatory cytokines such as TNF-α.

In adults and children, two RCTs utilizing phytopharmaceutical formulations of this extract show excellent protection against enveloped viruses, including coronaviruses. Preliminary published clinical results on SARS-CoV-2 may provide even more evidence that Echinacea can be used to combat this particular coronavirus.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Evolution of the SARS-CoV-2 spike protein in the human host. Image Credit: MattLphotography/Shutterstock

SARS-CoV-2 spike protein characteristics responsible for viral evolution in human hosts

by Medical Finance
May 20, 2022
0

In a recent study published in Nature Communications, a team of researchers from the United Kingdom (UK) assessed the structure...

Study: Model-based estimates of deaths averted and cost per life saved by scaling-up mRNA COVID-19 vaccination in low and lower-middle income countries in the COVID-19 Omicron variant era. Image Credit: cortex-film/ Shutterstock

Producing more mRNA COVID vaccines could save 1.5M lives in low/middle-income countries

by Medical Finance
May 20, 2022
0

In a recent study posted to the medRxiv* preprint server, a team of researchers from the United States estimated the...

Study: An efficient and cost-effective method for directed mutagenesis at multiple dispersed sites – a case study with Omicron Spike DNA. Image Credit: Naeblys/Shutterstock

Study explores the generation of SARS-CoV-2 Omicron Spike DNA construct using multiple site-targeted mutagenesis

by Medical Finance
May 20, 2022
0

In a recent study posted to the bioRxiv* pre-print server, a team of researchers demonstrated multiple site-directed mutagenesis as an...

Study: Decoding COVID-19 mRNA Vaccine Immunometabolism in Central Nervous System: human brain normal glial and glioma cells by Raman imaging. Image Credit: Kateryna Kon/Shutterstock

Effect of COVID-19 mRNA vaccine on in vitro glial cells of the brain studied by Raman spectroscopy and imaging

by Medical Finance
May 20, 2022
0

In a recent study posted to the bioRxiv* preprint server, researchers studied how messenger ribonucleic acid (mRNA)-based BNT162b2 coronavirus disease...

Study: SARS-CoV-2 ORF6 disrupts innate immune signalling by inhibiting cellular mRNA export. Image Credit: Design_Cells / Shutterstock

SARS-CoV-2 ORF6 inhibits mRNA export to favour viral translation and suppress innate signalling

by Medical Finance
May 20, 2022
0

A recent study posted to the bioRxiv* pre-print server investigated the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

Study: Evaluating the effectiveness of rapid SARS-CoV-2 genome sequencing in supporting infection control teams: the COG-UK hospital-onset COVID-19 infection study. Image Credit: peterschreiber.media/Shutterstock

Study explores rapid SARS-CoV-2 genome sequencing to help reduce hospital-acquired COVID-19 infections

by Medical Finance
May 20, 2022
0

In a recent study posted to the medRxiv* pre-print server, researchers examined whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

Next Post
Nutritional components hold promise for improving the health and well-being of adults

Molecular RNA profile of naked mole-rats reveals new insights on skin aging

Study: Anisodamine potently inhibits SARS-CoV-2 infection in vitro and targets its main protease. Image Credit: SKK Pix / Shutterstock

Compound found in Datura shows promise as antiviral agent against SARS-CoV-2

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • ImageForNews 710472 16497042443496728
    COVID-19 vaccines and reports of menstrual disorders
  • Study: Identification of a Novel SARS-CoV-2 Delta-Omicron Recombinant Virus in the United States. Image Credit: Ivan Marc/Shutterstock
    New SARS-CoV-2 Omicron-Delta recombinant virus identified in the US
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply